Literature DB >> 13960

Clinical pharmacokinetics of lorazepam. II. Intramuscular injection.

D J Greenblatt, T H Joyce, W H Comer, J A Knowles, R I Shader, A A Kyriakopoulos, D S MacLaughlin, H W Ruelius.   

Abstract

A single dose of 4 mg of lorazepam was injected into the deltoid muscles of six healthy male volunteers. Multiple venous blood samples were drawn during 48 hr after the dose and all urine was collected for 24 hr after the dose. Concentrations of lorazepam and its major metabolite, lorazepam glucuronide, were determined by electron-capture gas-liquid chromatography. Lorazepam was rapidly absorbed from the injection site, reaching peak concentrations within 3 hr. Mean pharmacokinetic pamrameters for unchanged lorazepam were: apparent absorption half-life: 21.2 min; elimination half-life: 13.6 hr; volume of distribution: 0.9 L/kg; total clearance: 58.2 ml/min. Lorazepam glucuronide rapidly appeared in plasma, reached peak concentrations within 12 hr of the dose, then was eliminated approximately in parallel with the parent drug. Within 24 hr a mean of 47.6% of the dose was recovered in the urine as lorazepam glucuronide and less than 0.5% was recovered as unchanged lorazepam.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 13960     DOI: 10.1002/cpt1977212222

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

Review 1.  Treatment of patients with cocaine-induced arrhythmias: bringing the bench to the bedside.

Authors:  Robert S Hoffman
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

2.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

3.  Clinical pharmacology and therapeutics of benzodiazepines.

Authors:  E M Sellers
Journal:  Can Med Assoc J       Date:  1978-06-24       Impact factor: 8.262

4.  The use of short- and long-acting hypnotics in clinical medicine.

Authors:  A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1981       Impact factor: 4.335

5.  Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.

Authors:  D J Greenblatt; M D Allen; D S MacLaughlin; D H Huffman; J S Harmatz; R I Shader
Journal:  J Pharmacokinet Biopharm       Date:  1979-04

6.  Pharmacokinetics and metabolism of various benzodiazepines used as hypnotics.

Authors:  D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

7.  Hypnotics: rebound insomnia and residual sequelae.

Authors:  A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of oxazepam and lorazepam.

Authors:  D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

9.  The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans. I. Absorption, distribution, elimination and metabolism of lormetazepam-5-14C.

Authors:  M Hümpel; V Illi; W Milius; H Wendt; M Kurowski
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

10.  The value of lorazepam in gas encephalography: a preliminary report.

Authors:  R W Loehning; C W Kerber
Journal:  Neuroradiology       Date:  1979-07-01       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.